Page 203 - Read Online

Page 12 of 13 Pan et al. Hepatoma Res 2024;10:3 https://dx.doi.org/10.20517/2394-5079.2023.44

growth factor receptor 2 ( FGFR2 ) gene rearrangements (FOENIX-CCA3). JCO 2020;38:TPS600. DOI
37. Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res
Commun 2021;27:100356. DOI PubMed
38. Farshidfar F, Zheng S, Gingras MC, et al; Cancer Genome Atlas Network. Integrative genomic analysis of cholangiocarcinoma
identifies distinct idh-mutant molecular profiles. Cell Rep 2017;18:2780-94. DOI PubMed PMC
39. Xiang X, Liu Z, Zhang C, et al. IDH mutation subgroup status associates with intratumor heterogeneity and the tumor
microenvironment in intrahepatic cholangiocarcinoma. Adv Sci 2021;8:e2101230. DOI
40. Lavacchi D, Caliman E, Rossi G, et al. Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions.
Pharmacol Ther 2022;237:108170. DOI
41. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced
cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669-77. DOI
42. Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer
2016;122:3838-47. DOI
43. Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the
ErbB pathway. Nat Genet 2014;46:872-6. DOI
44. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular
cancer. Cancer Chemother Pharmacol 2009;64:777-83. DOI
45. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary
cancers: results of an early phase II study with lapatinib. Oncology 2012;82:175-9. DOI
46. Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or
metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 2022;23:1558-
70. DOI
47. Ohba A, Morizane C, Ueno M, et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent
biliary tract cancer: HERB trial. Future Oncol 2022;18:2351-60. DOI PubMed
48. Lee CK, Chon HJ, Cheon J, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and
cisplatin: a multi-institutional phase 2 trial of the Korean cancer study group (KCSG-HB19-14). Lancet Gastroenterol 2023;8:56-65.
DOI
49. Xin HY, Sun RQ, Zou JX, et al. Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in
intrahepatic cholangiocarcinoma. JAMA Netw Open 2023;6:e231476. DOI PubMed PMC
50. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a
phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234-43. DOI PubMed
51. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med
2018;378:731-9. DOI PubMed PMC
52. Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82. DOI PubMed PMC
53. Jakubowski CD, Azad NS. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chin Clin Oncol
2020;9:2. DOI PubMed
54. Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. The emerging role of immunotherapy in intrahepatic cholangiocarcinoma.
Vaccines 2021;9:422. DOI PubMed PMC
55. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med
2022;387:120-31. DOI PubMed
56. Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS G12C Inhibition in cancer. N Engl J Med 2021;384:2382-93. DOI
PubMed PMC
57. Sun J, Chen Q, Ma J. Notch-Sox9 axis mediates hepatocyte dedifferentiation in kras(G12V)-induced zebrafish hepatocellular
carcinoma. Int J Mol Sci 2022;23:4705. DOI PubMed PMC
58. Zhou SL, Xin HY, Sun RQ, et al. Association of KRAS variant subtypes with survival and recurrence in patients with surgically
treated intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:59-65. DOI PubMed PMC
59. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov
2014;13:828-51. DOI PubMed PMC
60. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74. DOI
PubMed PMC
61. Blair HA. Sotorasib: first approval. Drugs 2021;81:1573-9. DOI
62. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384:2371-81. DOI
63. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell
2017;168:707-23. DOI PubMed PMC
64. Berchuck JE, Facchinetti F, DiToro DF, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced
biliary tract cancer. Ann Oncol 2022;33:1269-83. DOI
65. Uson Junior PLS, Majeed U, Yin J, et al. Cell-free tumor dna dominant clone allele frequency is associated with poor outcomes in
advanced biliary cancers treated with platinum-based chemotherapy. JCO Precis Oncol 2022;6:e2100274. DOI PubMed PMC